---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-22-000098"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T20:04:05.841652+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pfizer Q3 revenue $22.6B (-6% YoY); Adj. EPS $1.78 (+40%); raises FY2022 guidance

## Summary
- Reported diluted EPS $1.51 (+6%); Adjusted diluted EPS $1.78 (+40%) YoY.
- Paxlovid contributed $7.5B in Q3; Comirnaty revenue guidance raised to ~$34B for 2022.
- FY2022 revenue guidance raised to $99.5-102.0B; Adj. EPS guidance raised to $6.40-6.50.
- Completed Biohaven ($12.8B) and GBT ($5.6B) acquisitions early Q4 2022.
- Positive Phase 3 readouts for RSV vaccine, Prevnar 20 in pediatrics, and Talzenna/Xtandi combo.

## SEC filing metadata
- accession: 0000078003-22-000098
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800322000098/0000078003-22-000098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800322000098/pfe-20221101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-22-000098
- JSON: https://secwatch.observer/filing/0000078003-22-000098.json
- Plain text: https://secwatch.observer/filing/0000078003-22-000098.txt

## Key facts
- Earnings Releases
  PFIZER INC reported the third quarter of 2022 results: revenue $22,638, net income 8,608, EPS $1.51. Guidance raised.
  - Period: the third quarter of 2022
  - Revenue: $22,638
  - Net income: 8,608
  - EPS: $1.51
  - Guidance: raised
  - Result: reported results
  source text: months of 2022 and 2021 (5) are summarized below. OVERALL RESULTS ($ in millions, except per share amounts) Third-Quarter Nine Months 2022 2021 Change 2022 2021 Change Revenues $ 22,638 $ 24,035 (6%) $ 76,040 $ 57,450 32% Reported Net Income (2) 8,608 8,146 6% 26,378 18,586 42% Reported Diluted EPS (2) 1.51 1.42 6% 4.60 3.27 41% Adjusted Income (3) 10,172 7,279
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000007800322000098/0000078003-22-000098-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.